/BVXV
BVXV Stock - BiondVax Pharmaceuticals Ltd.
Healthcare|BiotechnologyNASDAQ
$1.36+0.74%
+$0.01 (+0.74%) • Sep 6
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.25
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BVXV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.35 – $1.37
TARGET (TP)$1.56
STOP LOSS$1.25
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.37
52W High$11.49
52W Low$0.63
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $2.75M | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-11,061,000 | $-34,829,000 | $1.04M | $-78,351,000 | $-20,463,000 |
| Net Income | $-531,000 | $-50,810,000 | $6.82M | $-124,112,000 | $-23,293,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.20 | $-36.00 | $6.15 | $-151.98 | $-35.64 |
Company Overview
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BVXVBeat Rate
67%
Last 9 quarters
Avg Surprise
+2577.9%
EPS vs Estimate
Beats / Misses
6/3
Last 12 quarters
Latest EPS
$1.11
Q3 2023
EPS Surprise History
Q4 21
No data
Q1 22
-217.6%
$-2.70vs$-0.85
Q2 22
+300.0%
$2.00vs$-1.00
Q3 22
+300.0%
$2.10vs$-1.05
Q4 22
-40.0%
$0.06vs$0.10
Q2 23
No data
Q2 23
No data
Q3 23
+222.0%
$1.11vs$-0.91
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Nov 29, 2023 | — | — | — | — |
Q3 2023 | Aug 11, 2023 | $-0.91 | $1.11 | +222.0% | ✓ BEAT |
Q2 2023 | May 15, 2023 | — | $1.20 | — | — |
Q2 2023 | Apr 17, 2023 | — | $0.30 | — | — |
Q4 2022 | Nov 30, 2022 | $0.10 | $0.06 | -40.0% | ✗ MISS |
Q3 2022 | Aug 25, 2022 | $-1.05 | $2.10 | +300.0% | ✓ BEAT |
Q2 2022 | Jun 1, 2022 | $-1.00 | $2.00 | +300.0% | ✓ BEAT |
Q1 2022 | Mar 28, 2022 | $-0.85 | $-2.70 | -217.6% | ✗ MISS |
Q4 2021 | Nov 30, 2021 | — | $-1.96 | — | — |
Q3 2021 | Aug 26, 2021 | — | $3.70 | — | — |
Q2 2021 | May 13, 2021 | $-0.99 | $-3.60 | -263.2% | ✗ MISS |
Q1 2021 | Mar 31, 2021 | — | $-1.85 | — | — |
Q3 2020 | Sep 30, 2020 | — | $11.97 | — | — |
Q3 2020 | Aug 20, 2020 | $0.10 | $11.20 | +11100.0% | ✓ BEAT |
Q2 2020 | Jun 12, 2020 | — | $12.50 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-1.00 | — | — |
Q4 2019 | Nov 26, 2019 | $0.30 | $5.70 | +1800.0% | ✓ BEAT |
Q3 2019 | Aug 28, 2019 | $0.20 | $20.20 | +10000.0% | ✓ BEAT |
Q2 2019 | Apr 30, 2019 | — | $18.10 | — | — |
Q1 2019 | Mar 31, 2019 | — | $0.24 | — | — |
Latest News
Loading news...
Frequently Asked Questions about BVXV
What is BVXV's current stock price?
BiondVax Pharmaceuticals Ltd. (BVXV) is currently trading at $1.36 per share. The stock has moved +0.74% today.
What is the analyst price target for BVXV?
No analyst price targets are currently available for this stock.
What sector is BiondVax Pharmaceuticals Ltd. in?
BiondVax Pharmaceuticals Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BVXV's market cap?
BiondVax Pharmaceuticals Ltd. has a market capitalization of $0.00 billion, making it a small-cap company.
Does BVXV pay dividends?
No, BiondVax Pharmaceuticals Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPTO
Aptose Biosciences Inc.
$1.71
Mkt Cap: $0.0B
CYTO
Altamira Therapeutics Ltd.
$0.30
Mkt Cap: $0.0B
FRTX
Fresh Tracks Therapeutics, Inc.
$0.94
Mkt Cap: $0.0B
GMDA
Gamida Cell Ltd.
$0.03
Mkt Cap: $0.0B
HILS
Hillstream BioPharma, Inc.
$0.24
Mkt Cap: $0.0B
NBRVF
Nabriva Therapeutics plc
$0.00
Mkt Cap: $0.0B
NEUP
Neuphoria Therapeutics Inc.
$3.89
Mkt Cap: $0.0B
TCDA
Tricida, Inc.
$0.11
Mkt Cap: $0.0B
TECX
Tectonic Therapeutic, Inc.
$19.56
Mkt Cap: $0.4B
TNFA
TNF Pharmaceuticals, Inc.
$5.20
Mkt Cap: $0.0B
Explore stocks similar to BVXV for comparison